

**FORMULATION DEVELOPMENT AND EVALUATION OF
MEDICATED CHOCOLATE OF ALBENDAZOLE****Amol Babasaheb Kolpe* and Prof. Rajendra K. Surawase**Department of Pharmaceutics, LN Dr. J D Pawar College of Pharmacy Manur, Kalwan,
Maharashtra.Article Received on
23 October 2020,Revised on 13 Nov. 2020,
Accepted on 03 Dec. 2020

DOI: 10.20959/wjpr20211-19074

Corresponding Author*Amol Babasaheb Kolpe**Department of Pharmaceutics,
LN Dr. J D Pawar College of
Pharmacy Manur, Kalwan,
Maharashtra.**ABSTRACT**


Formulation of Medicated Chocolate of Albendazole is formulated by using cocoa butter and cocoa powder. Mostly Pediatric patient have fear to take the Medicine as Albendazole formulation or any other formulation. with the help of this formulation we will provide most palatable and acceptable formulation for pediatric patient and minimize the fear about medicine. So we prepared formulation and evaluate with different parameter such as Drug release, Compatibility of Drug and Excipient, safety and organoleptic properties by using UV-spectroscopy, IR Spectroscopy, DSC. After Evaluation of all parameter we found satisfactory results with all parameter and conclude that this

developed formulation is successfully Developed and Evaluated.

KEYWORD: Albendazole (ALB), Coca powder, Coca Butter. Icing Sugar, Sodium Benzoate.

INTRODUCTION

Chocolate is highly sophisticated a versatile food that is combined to create totally likable taste and texture sensations. Chocolate is also an anhydrous medium and is therefore it is resistant to micro organism growth and to hydrolysis of water sensitive active agents. Chocolate is good vehicle for delivering active agents in many aspects. Chocolate is one of the most tasty, acceptable and favorite in children. Anthelmintics are the drugs that are used for the treatment against the infections caused by the worms, flukes, nematodes, round worms, tapeworms etc. Albendazole (ALB) is a benzimidazole carbamate with a broad spectrum anti-parasitic. In general, most ascariasis, trichuriasis, enterobiasis and hookworm, Tapeworm infections can be successfully treated with single dose ALB.



Chocolate is one of the most Tasty, likable palatable and favorite in children, so we have developed Albendazole Medicated chocolate. Hence, an attempt will be made to improve the patient compliance and palatability.

MATERIAL AND METHOD

Procurement of Drug and Excipients

The following drug, excipients and chemicals were used for the formulation and evaluation of chocolates of Albendazole.

Materials: The drug and excipients used in this work are given in Table no. 1.

Table 1: List of Chemicals.

S.N.	Drug and excipients	Supplier/Gifted by
1.	Albendazole	Medriech ltd. (Meiji seika pharma), Bangalore
2.	Cocoa butter	Pruthvi foods Pvt. Ltd, Ahmedabad
3.	Cocoa powder	Pruthvi foods Pvt. Ltd, Ahmedabad
4.	Milk Powder	Pruthvi foods Pvt. Ltd, Ahmedabad
5.	Icing sugar	Loba Chemie, Mumbai
6.	Sodium benzoate	Loba Chemie, Mumbai

Note: All the other chemicals like icing sugar, Dicalcium phosphate used are of analytical grade (AR).

Instruments and Equipments: The following equipments and instruments have been used in present research work.

Table 2: List of Equipments and Instruments.

S.N.	Name of Equipment and Instrument	Model	Make
1.	Digital electronic balance	BL-220H	Shimadzu
2.	UV-Visible Double Beam Spectrophotometer.	1601	Shimadzu
3.	Fourier transform infrared spectrophotometer	8400S	Shimadzu
4.	Hot Air Oven	—	Lab Hosp
5.	Differential Scanning Colorimeter	DSC 60	Shimadzu
6.	Vernier Caliper	—	Aerospace
7.	Magnetic Stirrer	—	Aerospace
8.	USP Tablet Dissolution Test Apparatus Type-II	DISSO 2000	Lab India
9.	Stability Chamber	—	Science Lab

Preparation of medicated chocolates

For the formulation of each chocolate form drug, cocoa butter, cocoa powder, milk powder, icing sugar and sodium benzoate were used. All ingredients were weighed accurately.

Formulation of chocolate Base

The sugar syrup prepared by heating the sugar (Pharmaceutical Grade) with Water in a beaker using a heating mantle at 50°C for 5-6 minute. The coca base is prepared by melt down the coca butter in a beaker for 2 minute and adding the above prepared sugar syrup then add milk powder and coca powder in it. This mixture is get cooled upto semisolid consistency and then add flavouring agent and mix it.

Formulation of medicated chocolate

Oven was preheated at 50°C. Then chocolate base was melted to obtained free pourable liquid. Albendazole and Sodium benzoate was added in chocolate base for uniform mixing. Above mixture was filled into pre calibrated polycarbonate set mould and refrigerated for 15 min till it become solid. Figure no. 1 showing the preparation of medicated chocolate. This solidified content was removed from mould carefully and evaluated using various evaluation parameters.



Figure 1: Preparation of medicated chocolate.

Table 3: Composition of medicated chocolates of Albendazole.

Sr. No.	Ingredients (gm)	F1	F2	F3	F4	F5	F6
1.	Albendazole	0.2	0.2	0.2	0.2	0.2	0.2
2.	Cocoa Butter	2.25	2	1.75	1.5	1.25	1
3.	Cocoa Powder	0.5	0.5	0.5	0.5	0.5	0.5
4.	Milk powder	1.2	1.2	1.2	1.2	1.2	1.2
5.	Icing Sugar	3.75	3.5	3.25	3	2.75	2.5
6.	Sodium Benzoate	0.05	0.05	0.05	0.05	0.05	0.05
	Total Weight	7.95	7.45	6.95	6.45	5.95	5.45

RESULTS AND DISCUSSION

Preformulation Study of Albendazole

Organoleptic properties and description, Melting Point, Solubility:

Table 4: Organoleptic properties and description.

Property	Observation
Organoleptic properties	Slightly white to pale buff colored powder.
Melting Point	209°C, which matches with the reported value.
Solubility	freely soluble dimethylsulfoxide,HCL,NaOH

FTIR studies of Albendazole

Figure 2: Shows the IR spectra of pure drug.




Figure 2: FTIR spectra for the drug Albendazole.

Table 5: The functional groups detection by using wave numbers.

Functional groups	Wave numbers (cm ⁻¹)	Standard frequency range
CH ₃ /CH ₂ C-H stretching	2929.77	2850-3000
C=O Stretch.	1747.57	1680-1880
CH ₃ /CH ₂ C-H stretching	2860.53	2850-3000
-C=N	1579.75	1375-1500
N-H stretch of amido gr.	3064.99	3500-3100
C-O Stretch.	1053.17	1000-1350
C=O Stretch.	1747.57	1680-1880
C-S-C stretch.	961.60	800-1000

Interpretation

Table No. 5 Shows the interpretation of the peaks obtained in the Infra Red spectra along with their corresponding functional groups.

DSC Studies of Albendazole




Figure 3: DSC thermogram of Albendazole.

Table 6: DSC peaks of Albendazole.

Drug	Melting point	Interpretation		
		Onset	Peak	End set
Albendazole	208 ⁰ -210 ⁰ C	193.54°C	205.75°C	215.35°C

Spectroscopic studies (Determination of λ_{max}) of Albendazole

The UV spectrum, obtained after the proper dilution of the drug shown in Figure No. 10. The drug solution was scanned and wavelength was found to be 291 nm. The spectrum was showing λ_{max} at 291 nm, hence all further analysis was done by using the wavelength 291 nm.




Figure 4: The UV-spectra of pure Albendazole in phosphate buffer pH 6.8.

Evaluation parameters for formulated Albendazole Medicated chocolates.

Sr. No.	Formulation code	Appearance /Texture	Colour	Taste	Odour	Shape	Weight variation (gm)*	Thickness (mm)**
1.	F1	Glossy, even shine, no streaks	Dark brown	Semi-sweet	Pleasant and fresh chocolaty	Round shape	7.96±0.24	9.18±0.04
2.	F2	Glossy, even shine, no streaks	Dark brown	Sweet, good after taste	Pleasant and fresh chocolaty	Round shape	7.48±0.26	8.99+0.03
3.	F3	Glossy, even shine, no streaks	Dark brown	Neither bitter nor sweet	Pleasant and fresh chocolaty	Round shape	6.96±0.32	8.75+0.01
4.	F4	Glossy, even shine, no streaks	Dark brown	Semi-sweet	Pleasant and fresh chocolaty	Round shape	6.46±0.30	8.50+0.11
5.	F5	Glossy, even shine, no streaks	Dark brown	Neither bitter nor sweet	Pleasant and fresh chocolaty	Round shape	5.95±0.44	8.15+0.13
6.	F6	Glossy, even shine, no streaks	Dark brown	Bitter	Pleasant and fresh chocolaty	Round shape	5.44±0.27	8.03+0.12

Evaluation parameters for formulated Albendazole Medicated chocolates

Sr. No.	Formulation code	Drug content (%)**	Melting point (°C)	% moisture content
1.	F1	100.06+0.04	36.0°C	8.36
2.	F2	99.56+0.04	34.0°C	6.28
3.	F3	99.36+0.08	34.5°C	7.90
4.	F4	99.97+0.08	35.0°C	10.27
5.	F5	99.21+0.08	34.5°C	8.99
6.	F6	99.06+0.04	35.5°C	8.20

6.1.1. Blooming test


Table 6: Blooming test of Albendazole chocolate (Optimized batch F1).

Sr. No.	Storage Condition	Evaluated Condition	Fat Bloom	Sugar Bloom
1.	Refrigerated Condition (2-8°C) for 24 hr.	At Room Temperature	No Blooming	No Blooming
2.	Room Temperature (25°C) for 24 hr.	At Refrigerated Condition	No Blooming	No Blooming

6.1.2. In-vitro dissolution study

Table 7: % Cumulative drug release of Albendazole chocolate.

Formulation Code	Time (Min.)				
	4	8	12	16	20
F1	48.46	59.33	73.76	84.87	99.55
F2	41.53	52.33	63.24	81.17	95.81
F3	34.61	45.34	56.18	77.5	92.11
F4	31.15	41.85	52.65	73.93	91.97
F5	27.69	38.35	49.11	70.37	90.1
F6	24.23	34.85	45.58	70.26	90



6.1.3. Stability Studies

Table no. 18 showing the data of short-term stability study of optimize batch

Table 8: Stability Studies of Formulation F1.

Code	% Drug Release Data				Drug Content	Melting point	Appearance
	Initial	10th day	20th day	30th day			
F1	99.5	99.16	98.76	98.70	99.99	34.5°C	Acceptable

6.2. Drug release kinetics- model fitting of the dissolution data

The release rate constant (k) of mathematical models for *in vitro* drug release of all formulations are Shown below in table no. 19.

Release rate constant (k) = Slope* 2.303

Table 9: Results of drug release kinetics model.

Code	Zero order		First order		Higuchi Equation		Korsmeyer-Peppas			Mechanism of drug release
	R ²	K	R ²	K	R ²	K	R ²	K	N	
F1	0.997	7.35	0.843	0.17	0.978	47.3	0.976	1	0.43	Non-fickian transport
F2	0.989	7.91	0.844	0.15	0.956	50.52	0.960	1.2	0.52	Non-fickian transport
F3	0.982	8.47	0.877	0.12	0.946	54	0.954	1.4	0.61	Non-fickian transport
F4	0.977	8.85	0.853	0.12	0.935	56.23	0.955	1.52	0.66	Non-fickian transport
F5	0.973	9.03	0.849	0.11	0.929	57.27	0.954	1.65	0.71	Non-fickian transport
F6	0.968	9.61	0.851	0.11	0.921	60.89	0.95	1.85	0.80	Non-fickian transport

CONCLUSION

In present dissertation work, an attempt was made to formulate medicated chocolate of Albendazole using cocoa butter, cocoa powder and milk powder for the treatment of helminth infection. The aim of this research work was to formulate and evaluate medicated chocolate of Albendazole for pediatric patient, in view to improve patient compliance. The medicated chocolates were evaluated for shape, colour, texture, fragrance, dimension, taste, weight, blooming test, melting point, % drug content and dissolution study. Each chocolate of Albendazole contains 200mg drug. All the data of in-vitro drug release studies was fitted into various models like zero order, first order, Higuchi, and Korsmeyer-Peppas model. The formulation batch F1 shows the maximum correlation coefficient. Hence it can be concluded that the formulation F1 will be useful for treatment of helminths infection.

“So, the medicated chocolates of Albendazole is a best choice to bypass the hepatic first pass metabolism with an improvement in the bioavailability of Albendazole.”

ACKNOWLEDGEMEN

I would like to thank first and foremost to my parents who instilled me the desire to do my best at whatever I attempted, and with that hard work I was capable of anything. Without them I would not be where I am now.

I express whole hearted gratitude to my guide Mr. R.K. Surawase, Head of dept. of Pharmaceutics For suggesting solutions to problems faced by me and providing indispensable guidance, tremendous encouragement at each and every step of this dissertation work My

immense privilege and profound gratitude to Dr. Avish D. Maru, Principal of Loknete Dr. J. D. Pawar College of Pharmacy, Manur, Kalwan. For furnishing all the necessary facilities with whole hearted support which enable to me for complete this project work in a grand successful manner. My sincere thanks to Mr. Kishor K. Kothawade, Principal of S.G.S.S. College of Pharmacy, Manur, Kalwan for his support and encouragement. I gratefully acknowledge Mr. M. P. Sonawane, Vice Principal of College who was the source of continuous inspiration and encouragement. I would like to vote of thanks to Dr. S. Surana, Dr. M. Khan, Mr. V. Jadhav, Mr. D. Kawade, Mr. T. Bagul, Mr. Z. Haque, Smt. S. Kamble, Ms. J. Bhadane, Mrs. B. Sonawane, Mr. Z. Ansari and Mr. L. Birari for their moral support, suggestions, involvement in the work and extending their guidance whenever required during course of this study. I am highly grateful to the non-teaching staff for their support. I am thankful to all my seniors, classmates, friends, and juniors and my special thanks to Mr. Shivraj Pagare, Ms. Kajal Patil, Ms. Suvarna Vadge, Ms. Rohini Patil, Ms. Dipika Pawar, Ms. Pallavi Deore, Mr. Sanket Shinde and Mr. Uday Sonawane.

It is very difficult task to acknowledge the services to thank all those gentle people. So I would like to thank all those people who have helped me directly or indirectly to complete this project work success.

REFERENCES

1. Carstensen JT. *Pharmaceutics of Solids and Solid Dosage Forms*. Wiley Interscience, New York, 1977.
2. Gennaro A R. *Remington the Science and Practice of Pharmacy*. 20th ed. Philadelphia: Lippincott Williams & Wilkins.
3. Lachman L, Lieberman H A, Kanig J L. *The theory and practice of industrial pharmacy*. 3rd ed. Mumbai: Varghese Publishing House, 1990.
4. Radha Bhati et al., A detailed review on oral mucosal drug delivery system, *International Journal of Pharmaceutical Sciences and Research*, 2012; 3(1): 659 -681.
5. Squier C.A. et al., *The Permeability of Oral Mucosa*, *Critical Reviews in Oral Biology and Medicine*, 1991; 2(1): 13-32.
6. Rathbone J. and Hadgraft J., *Absorption of drug from the human oral cavity*, *International Journal of Pharmacy*, 1991; 79: 9-24.
7. Harris D. and Robinson, *Drug delivery via the mucous membrane of the oral cavity*, *Journal of Pharmaceutical Science*, 1992; 81: 1-10.

8. Md Habban Akhter et al., A comprehensive review on mucoadhesive buccal drug delivery, International Journal of Pharmaceutical Research and Development, 2012; 3(11): 59-77.
9. Marc B. Brown et al., Advances in oral transmucosal drug delivery, Journal of controlled release, 2011; 153: 106-116.